Same molecule, different route
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: it mimics a natural gut hormone released after eating, acting on appetite-regulating areas of the brain to increase fullness, reduce hunger and dampen food cravings.[2] That mechanism is identical whether the semaglutide arrives as a weekly injection or a daily tablet, because it is the same active ingredient in both.[1]
The injection came first — a once-weekly subcutaneous injection.[9] The pill is that same molecule reformulated as a once-daily oral tablet, which Novo Nordisk describes as the first oral GLP-1 receptor agonist licensed for weight management in adults.[1] So the honest headline is not a new drug but a new way to take an existing one, and the differences are all about route.
Pill and injection are the same semaglutide working the same way. The choice between them is a choice about route and routine — daily tablet with strict timing versus weekly injection with none — and it is made with a prescriber, weighing your history and preferences.
The two forms side by side
The pill and the injection use completely different dose numbers, so it helps to set out what each involves.
| Wegovy pill | Wegovy injection | |
|---|---|---|
| Route | Oral tablet, swallowed[1] | Subcutaneous injection, under the skin[9] |
| Frequency | Once daily[1] | Once weekly[9] |
| Maintenance dose | 25 mg once daily[1] | 2.4 mg once weekly[2] (7.2 mg once weekly if needed for weight management in adults with obesity)[9] |
| Timing rules | Empty stomach, small amount of water, then a wait before eating[2] | No food or water timing rules |
| Licensed use | Weight management[1] | Weight management[5] |
The dose numbers are a trap: a 25 mg daily tablet and a 2.4 mg weekly injection are not a tenfold difference in "strength". They are different formulations absorbed in different ways — only a fraction of an oral dose crosses the stomach lining at all — so the milligrams on the box cannot be compared.
How the routine differs
For most people the real decision is less about the science than about which routine they can keep to — and here the two forms genuinely diverge.
The pill: convenient, but disciplined
The tablet's appeal is that there are no needles; the catch is timing. Semaglutide is a peptide that is poorly absorbed from the gut, so the oral version is co-formulated with an absorption enhancer, salcaprozate sodium (SNAC), which helps a small amount be absorbed, mainly in the stomach.[8] Food and larger amounts of water reduce that absorption, so the instructions are strict: take it first thing on an empty stomach, with only a small amount of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medicines.[2][8] The UK product information adds that it should be swallowed whole, not split, crushed or chewed.[8] One point in its favour: the UK patient leaflet says it needs no special temperature storage, only keeping in its original pack to protect it from light and moisture, so unlike some injectables it does not need a fridge.[6] None of this is difficult, but it is daily, and must become a fixed habit for the medicine to absorb properly. Our dosage and how-to-take page covers the routine in full.
The injection: less frequent, no timing rules
The injection reverses the trade-off. There are no food or water rules and nothing to wait for — but it is an injection under the skin, which some people find a barrier in itself. Its rhythm is weekly rather than daily: fewer things to remember, though it means handling and, for some products, storing a device. We do not reproduce the injection's dose ladder here; its maintenance dose is 2.4 mg once weekly,[2] and its current UK label (revised August 2026) allows an increase to 7.2 mg once weekly, if needed for weight management in adults with obesity, after at least 4 weeks on 2.4 mg.[9]
What the trials show — and what they can't tell you
This is the part most comparisons get wrong. The tablet's weight-management evidence comes from the OASIS programme; the study behind the approved 25 mg dose was OASIS 4, which ran for 64 weeks in adults with obesity, or overweight with weight-related complications, without type 2 diabetes, comparing oral semaglutide 25 mg against placebo alongside lifestyle support.[3] Novo Nordisk reports mean weight loss of about 16.6% among people who took the tablet as intended,[1] against 2.8% on placebo on the same measure in the UK product information.[10] Across everyone regardless of how consistently they took it, mean weight loss was about 13.6% versus 2.2% on placebo, according to the UK product information.[10] Around 76% of people on the tablet lost at least 5% of their body weight, versus about 31% on placebo.[4]
Here is the honest limit: those figures come from the tablet's own trials. Our sources contain no head-to-head study that put one group on the pill and another on the injection — the injection's evidence was gathered separately, in different populations, over different lengths, counting drop-outs differently. Laying the pill's percentage next to an injection percentage from another study, as if the gap meant something, is a well-worn mistake rather than a real comparison. If you see a confident claim that one form gives "more" weight loss than the other, check whether it rests on a trial that actually compared them.
Side effects: broadly similar, per the manufacturer
Because it is the same molecule, the side-effect story is largely shared. Both forms are dominated by gastrointestinal effects — nausea, diarrhoea, vomiting, constipation, stomach pain — alongside headache and tiredness,[4] reported most often while the dose is being increased.[8] In OASIS 4, gastrointestinal adverse events affected about 74% of people on the tablet against 42% on placebo, and were mostly mild to moderate; the share who stopped because of side effects was similar between drug and placebo, at about 7% versus 6%.[3][4] Novo Nordisk describes the tablet's safety profile as comparable to previous semaglutide weight-management studies, and the UK product information says it is consistent with the semaglutide injection trials.[1][8] Our sources do not provide a symptom-by-symptom comparison in the same study, so — as with efficacy — we do not claim one form is gentler than the other.
Semaglutide carries a boxed warning in the US about a risk of thyroid C-cell tumours, based on animal studies, and the US label says it should not be used by people with certain thyroid or endocrine conditions;[4] the UK product information for the tablet lists only one formal contraindication, allergy to its ingredients, and says it should not be used in pregnancy or while breastfeeding.[8] Those cautions apply to the medicine, whichever form it takes, and they are decisions for a prescriber who knows your history. If you take any weight-loss medicine and experience side effects, you can report them through the MHRA Yellow Card scheme[7] and should speak to your GP or pharmacist. Our side effects page covers the warnings and cautions in full.
Switching between the two forms
Because both are semaglutide, moving between them is possible under a prescriber's direction. The MHRA says that someone already established on the 2.4 mg once-weekly injection can be transitioned directly to the 25 mg once-daily tablet.[2] That is a managed clinical change, not a swap to make on your own — the dose numbers are not comparable, and only a prescriber can set the plan.
The reverse direction is now written into the injection’s own UK label. Since the August 2026 revision of the Wegovy pen Summary of Product Characteristics, it states that people taking the 25 mg tablet once daily can be transitioned to the 2.4 mg once-weekly injection, starting the injection the day after their last tablet; the tablet’s label covers the other direction, with tablets starting one week after the last injection.[9][8] Either way it is the prescriber who sets the timing.
Who might prefer which — a prescriber's call
It is tempting to want a rule of thumb, and that is exactly what to resist. The features above map onto preferences in obvious ways: someone who dislikes needles may be drawn to a tablet; someone who would struggle with a strict daily empty-stomach routine, or who prefers a weekly task they can otherwise forget, may find the injection easier to keep to. But those are starting points for a conversation, not a self-diagnosis. The choice also turns on things a page cannot see: your other medicines, your medical history, how you have tolerated GLP-1 medicines before, and clinical suitability for either form. That is why both forms are something a prescriber may discuss with you, never something you decide to take. The frequently asked questions and the development story behind the tablet can help you go into that conversation better informed.
How you would access either in the UK
Both forms are prescription-only medicines, so there is no lawful way to buy either without a consultation. A qualified prescriber assesses whether treatment is appropriate and which form fits, and a GPhC-registered pharmacy dispenses it against that prescription. At approval the tablet was not on the NHS, with access depending on a NICE evaluation still to be completed,[2] so any supply was on private prescription. That mirrors how the injectable form reached the NHS — appraised, then offered only to defined groups of patients.[5] A site offering to sell semaglutide in any form with no prescription and no assessment is not operating lawfully, and what it supplies may not be a genuine, regulated medicine.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
Our sources contain no head-to-head trial comparing the two, so a clean side-by-side answer does not exist. What is published is OASIS 4, which reported mean weight loss of about 16.6% on oral semaglutide 25 mg taken as intended,[1] and about 13.6% regardless of adherence,[4] versus roughly 2–3% on placebo over 64 weeks. Those figures come from a separate trial in a separate group of people from the injection's studies, so they cannot simply be lined up against each other.
Can I switch from the Wegovy injection to the pill?
The MHRA says that someone established on the 2.4 mg once-weekly injection can be transitioned directly to the 25 mg once-daily tablet.[2] That is a plan for a prescriber to make and manage, not something to do on your own — the two forms use different dose numbers.
Why does the pill have to be taken on an empty stomach when the injection doesn't?
Semaglutide is a peptide, normally broken down in the stomach before it can be absorbed. The tablet contains an absorption enhancer, but even so only a small amount is absorbed, and food or extra water reduce it further — so it must be taken on an empty stomach with a little water and a wait before eating.[2][8] An injection bypasses the stomach entirely, so it has no food or water timing rules.
Which has fewer side effects, the pill or the injection?
Both are the same molecule and both are dominated by gastrointestinal effects. Novo Nordisk describes the tablet's safety profile as comparable to previous semaglutide weight-management studies, and the UK product information says it is consistent with the semaglutide injection trials.[1][8] Our sources contain no reliable symptom-by-symptom comparison, so we cannot say one form has fewer side effects. Report any side effect through the MHRA Yellow Card scheme.[7]
Is the pill or the injection better?
There is no single "better" form. They contain the same active ingredient and differ in route and routine: a tablet once a day with strict timing, or an injection once a week with none. Which trade-off suits someone depends on preferences, medical history and other medicines — which is why the choice belongs to a qualified prescriber.
Further reading
- The Wegovy pill’s empty-stomach rule, and why it exists
- How the Wegovy pill works: oral semaglutide explained
References
- Novo Nordisk. Wegovy pill (oral semaglutide 25 mg) FDA approval announcement — first oral GLP-1 for weight management, once-daily 25 mg dosing, and the OASIS 4 adherent-estimand result (about 16.6% mean weight loss when treatment was adhered to). novonordisk.com
- Medicines and Healthcare products Regulatory Agency (MHRA) / GOV.UK. "First GLP-1 tablet for weight loss approved in the UK" — press release, 11 June 2026: the UK licence (June 2026), the mechanism, the taking-it rules (on an empty stomach after fasting for at least 8 hours, with a sip of water, then no food or drink for at least 30 minutes), the 2.4 mg once-weekly injection dose and the direct switch to the 25 mg once-daily tablet, and the NHS position (not currently available on the NHS; decisions on NHS use to follow established processes, including a NICE evaluation). gov.uk
- Wharton S, Lingvay I, Bogdanski P, et al. "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity" (OASIS 4). New England Journal of Medicine, 18 September 2025;393:1077–1087 — design, body-weight change at week 64 (−13.6% vs −2.2% with placebo) and gastrointestinal adverse events (74.0% vs 42.2%). doi.org/10.1056/NEJMoa2500969 Trial registration: ClinicalTrials.gov NCT05564117. clinicaltrials.gov
- US Food and Drug Administration. Wegovy (semaglutide) injection and tablets — US Prescribing Information, revised 06/2026 (via DailyMed): the common side-effect list, the boxed warning on thyroid C-cell tumours and the contraindications, and the 25 mg tablet trial results (−13.6% body-weight change; at least 5% weight loss in 76.3% vs 31.3% on placebo; 6.9% vs 5.9% stopping treatment because of adverse reactions). dailymed.nlm.nih.gov
- National Institute for Health and Care Excellence. TA875: semaglutide for managing overweight and obesity (injectable form; context for the pill's likely NHS route). nice.org.uk
- Novo Nordisk. Wegovy tablets — UK patient information leaflet (revised 06/2026), section 5, storage: store in the original package to protect from light and moisture; no special temperature storage conditions. medicines.org.uk
- MHRA. Yellow Card scheme — report a suspected side effect. yellowcard.mhra.gov.uk
- Novo Nordisk. Wegovy 25 mg tablets — UK Summary of Product Characteristics, section 4.2 (on an empty stomach after fasting for at least 8 hours, swallowed whole with a sip of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines; tablets should not be split, crushed or chewed, as it is not known whether this impacts absorption; patients on the 2.4 mg weekly injection can start tablets one week after their last injection), section 4.3 (hypersensitivity to semaglutide or any excipient is the only contraindication), section 4.6 (not to be used in pregnancy or breast-feeding) section 4.8 (safety profile consistent with the semaglutide injection trials; gastrointestinal side effects reported most often during dose escalation) and section 5.2 (low oral bioavailability; co-formulated with salcaprozate sodium, which facilitates absorption, mainly in the stomach; absorption reduced by food or large volumes of water); text revised 06/2026. medicines.org.uk
- Novo Nordisk. Wegovy 0.25–2.4 mg solution for injection in pre-filled pen — UK Summary of Product Characteristics, section 4.2 (text revised 08/2026, published on emc 1 September 2026): switching from semaglutide tablets to the injection, and the option to increase the 2.4 mg maintenance dose to 7.2 mg once weekly, if needed for weight management in adults with obesity, after at least 4 weeks on 2.4 mg. medicines.org.uk
- Novo Nordisk. Wegovy 25 mg tablets — UK Summary of Product Characteristics, section 5.1, Table 2 (OASIS 4 results at week 64: body-weight change −13.6% vs −2.2% with placebo, treatment-policy analysis; −16.6% vs −2.8% if all patients had stayed on treatment); text revised 06/2026. medicines.org.uk